Skip to main content
SYS · ONLINEPASS · 63.0%
Open Assay
Independent Testing / Est. 2026
BATCH04·26·B
PASS63.0%
N27
PeptidesLongevityOvagen

Ovagen

/ Khavinson-tradition liver/ovarian bioregulator (Glu-Asp-Leu and related)
SPECULATIVEN = 0 · TESTING PENDING

ALIAS · EDL · Liver/ovarian peptide bioregulator

Pass rate
0
Samples
0
Suppliers
Research use onlyAny dose figures below describe what specific cited studies used, reported factually. Nothing on this page is guidance for human use.READ FIRST →

Terms in this page you can click for a plain-English popup: , , , , , , , .

§ A · Identity
Primary sequenceEDL
MW · CLASS · Khavinson-tradition liver/ovarian bioregulator (Glu-Asp-Leu and related)CATEGORY · Longevity

Tier 4. Khavinson-tradition short-peptide preparation positioned variably as a liver or ovarian bioregulator depending on vendor. The disclosed active sequence Glu-Asp-Leu (EDL) appears in Khavinson-group class-level reviews. No PubMed-indexed primary literature on Ovagen as a distinct preparation.

§ B · Mechanism of action

Ovagen is described in vendor materials as a Glu-Asp-Leu (EDL) tripeptide preparation. Within the Khavinson-tradition framework the claim is tissue-specific regulation of liver and ovarian cell gene expression. The molecular target has not been characterised in independent primary literature, and the same vendor channel markets EDL under both liver and ovarian indications without consistent disclosure of the basis for the dual claim.

§ C · Human clinical evidence

Tier 4. No PubMed-indexed primary literature on Ovagen / EDL as a distinct molecular entity. Class-level Russian-origin reviews from the Khavinson group only.

§ F · Safety signal

No formal human safety database. General class concerns for Khavinson-tradition short-peptide preparations apply.

§ H · Regulatory status

Regulatory status

FDA status:
Not FDA-approved
§ I · Notable gaps and controversies

The Khavinson school (Saint-Petersburg Institute of Bioregulation and Gerontology) has published an extensive body of work on short-peptide 'bioregulators' derived from animal-tissue extracts, with a unifying claim that tissue-specific tetrapeptides (and shorter motifs) regulate gene expression and tissue-specific cell function. The corpus is Russian-origin and substantially self-cited; independent Western replication of the foundational findings has not been established.

Ovagen carries a particular indication-ambiguity issue: the same vendor preparation is marketed for liver and for ovarian use, with no independent published basis for the dual tissue claim. The tissue-specific framework that underpins the Khavinson tradition cannot consistently support a single peptide regulating two anatomically distinct tissues.